首页> 美国卫生研究院文献>Thieme Open Access >Editorial Compilation V: To What Extent Are the Terminal Stages of Sepsis Septic Shock Systemic Inflammatory Response Syndrome and Multiple Organ Dysfunction Syndrome Actually Driven by a Prion/Amyloid Form of Fibrin?
【2h】

Editorial Compilation V: To What Extent Are the Terminal Stages of Sepsis Septic Shock Systemic Inflammatory Response Syndrome and Multiple Organ Dysfunction Syndrome Actually Driven by a Prion/Amyloid Form of Fibrin?

机译:社论编辑V:脓毒症败血性休克全身性炎症反应综合征和多器官功能障碍综合征的终末阶段实际上是由Pri蛋白/淀粉样蛋白纤维蛋白驱动的吗?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A well-established development of increasing disease severity leads from sepsis through systemic inflammatory response syndrome, septic shock, multiple organ dysfunction syndrome, and cellular and organismal death. Less commonly discussed are the equally well-established coagulopathies that accompany this. We argue that a lipopolysaccharide-initiated (often disseminated intravascular) coagulation is accompanied by a proteolysis of fibrinogen such that formed fibrin is both inflammatory and resistant to fibrinolysis. In particular, we argue that the form of fibrin generated is amyloid in nature because much of its normal α-helical content is transformed to β-sheets, as occurs with other proteins in established amyloidogenic and prion diseases. We hypothesize that these processes of amyloidogenic clotting and the attendant coagulopathies play a role in the passage along the aforementioned pathways to organismal death, and that their inhibition would be of significant therapeutic value, a claim for which there is considerable emerging evidence.
机译:疾病严重程度不断提高的公认发展是由于败血症引起的全身性炎症反应综合征,败血性休克,多器官功能障碍综合征以及细胞和机体死亡。较少被讨论的是与此同时伴随的同样完善的凝血病。我们认为,脂多糖引发的(通常是弥散性的)血管内凝血伴随着纤维蛋白原的蛋白水解,从而形成的纤维蛋白既具有炎症性又对纤维蛋白溶解具有抗性。特别是,我们认为生成的纤维蛋白形式本质上是淀粉样蛋白,因为它的许多正常α-螺旋含量都转化为β-折叠,就像在已建立淀粉样蛋白和ogenic病毒疾病中的其他蛋白质一样。我们假设淀粉样蛋白凝结和伴随的凝血病的这些过程在沿上述机体死亡途径的传递中起作用,并且它们的抑制将具有显着的治疗价值,对此有大量新证据表明。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号